The ultimate goal of this revised proposal is to understand the molecular pathogenesis of human acute myeloid leukemia (AML), using the AML-1/ETO chimeric transcription factor as a model system. The t(8;21) translocation, seen in the M2 subtype of AML, invariably generates AML-1/ETO fusion transcript which results in the expression of a chimeric transcription factor protein. The applicant has demonstrated that the normal AML-1B protein, but not the normal AML-1A protein, can transactivate the human GM-CSF promoter via a TGTGGT sequence located between bp-57 and -52 and can transactivate the human IL-3 promoter via a similar sequence. The AML-1/ETO protein can inhibit transcription from these promoters and can act as a dominant negative regulator of the GM-CSF promoter.
The Specific Aims of this proposal are to 1) define the basis for the differential effects of the normal AML-1A and AML-1B proteins and the AML- 1/ETO fusion protein on a) the activity of the human GM-CSF and IL-3 promoters and b) the regulation of bcl-2 expression in AML cell lines and the prevention of apoptosis; 2) identify cellular partners capable of interacting with AML- 1/ETO using a) the yeast two-hybrid system and b) bacterially or mammalian cell expressed AML-1/ETO fusion proteins; and 3) determine the effects of introducing the AML-1/ETO fusion gene on the proliferation and differentiation of normal hematopoietic progenitor cells and acute myeloid leukemia cell lines. These studies will define the interactions of AML-1/ETO with its DNA recognition sequences and with other cellular proteins. This study will also demonstrate whether AML-1/ETO generates anti-apoptotic signals and whether it has transforming activity by itself. Understanding how the AML-1/ETO fusion protein alters the cells' proliferation and differentiation program may provide insights into the pathogenesis of AML.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK043025-09
Application #
2684206
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Badman, David G
Project Start
1990-09-01
Project End
2000-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
9
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Wang, Lan; Huang, Gang; Zhao, Xinyang et al. (2009) Post-translational modifications of Runx1 regulate its activity in the cell. Blood Cells Mol Dis 43:30-4
Moldenhauer, Anja; Frank, Richard C; Pinilla-Ibarz, Javier et al. (2004) Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol 76:623-33
Mulloy, James C; Cammenga, Jorg; MacKenzie, Karen L et al. (2002) The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 99:15-23
Burns, Caroline Erter; DeBlasio, Tony; Zhou, Yi et al. (2002) Isolation and characterization of runxa and runxb, zebrafish members of the runt family of transcriptional regulators. Exp Hematol 30:1381-9
MacGrogan, D; Alvarez, S; DeBlasio, T et al. (2001) Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines. Oncogene 20:4150-60
Alvarez, S; MacGrogan, D; Calasanz, M J et al. (2001) Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization. Genes Chromosomes Cancer 32:285-93
Jakubowiak, A; Pouponnot, C; Berguido, F et al. (2000) Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem 275:40282-7
Klampfer, L; Cammenga, J; Wisniewski, H G et al. (1999) Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood 93:2386-94
Frank, R C; Sun, X; Berguido, F J et al. (1999) The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene 18:1701-10
Mao, S; Frank, R C; Zhang, J et al. (1999) Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol Cell Biol 19:3635-44

Showing the most recent 10 out of 25 publications